Neurogene Inc reports results for the quarter ended September 30 - Earnings Summary

Neurogene

18/11/2024 23:08

* Neurogene Inc  NGNE.OQ  reported a quarterly adjusted loss
of
$1.19​​ per share for the quarter ended September 30, higher
than the same quarter last year, when the company reported EPS
of $-1.64.  The mean expectation of six analysts for the quarter
was for a loss of $1.22 per share. Wall Street expected
results to range from $-1.34 to -89 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Neurogene Inc's reported EPS for the quarter was a loss of
$1.19​.
    * The company reported a quarterly loss of $20.22 million.
    * Neurogene Inc shares had fallen by 17.7% this quarter and
gained 78.1% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 16.3%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 7 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "strong buy"

Wall Street's median 12-month price target for Neurogene Inc is
$60.00 
This summary was machine generated from LSEG data November 18 at
11:07 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -1.22          -1.19          Beat
 Mar. 31 2024      -1.05          -1.09          Missed
 Mar. 31 2024      -1.13          -1.00          Beat
 Dec. 31 2023      -1.17          -1.64          Missed